Excerpt

Striving towards a person-centred service through joint working across health and social care and cross-sector working (for example with commercial organisations) achieves the best possible outcomes for the person. This incorporates a patient's values and preferences and minimises harm, supporting effective medicines optimisation. This guideline reviews the evidence available to support health and social care practitioners, and health and social care organisations, in considering the systems and processes required to ensure safe and effective medicines optimisation.

In this guideline, the term ‘medicines’ covers all healthcare treatments, such as oral medicines, topical medicines, inhaled products, injections, wound care products, appliances and vaccines. The guideline will assume that prescribers will use a medicine's summary of product characteristics to inform decisions made with individual patients.

Contents

• Guideline development group members
• Acknowledgements
• 1. Introduction
  • 1.1. Introduction
  • 1.2. Person-centred care
  • 1.3. Strength of recommendations
• 2. Development of a NICE clinical guideline
  • 2.1. What is a NICE guideline
  • 2.2. Remit
  • 2.3. Who developed the guideline
  • 2.4. What this guideline covers
  • 2.5. What this guideline does not cover
  • 2.6. Related NICE guidance
• 3. Methods
  • 3.1. Developing the review questions and outcomes
  • 3.2. Identifying the evidence
  • 3.3. Reviewing the evidence
  • 3.4. Evidence of cost effectiveness
  • 3.5. Developing recommendations
• 4. Guideline summary
  • 4.1. Key priorities for implementation
  • 4.2. Full list of recommendations
  • 4.3. Who should take action
• 5. Systems for identifying, reporting and learning from medicines-related patient safety incidents
  • 5.1. Introduction
  • 5.2. Review question
  • 5.3. Evidence review
  • 5.4. Health economic evidence
  • 5.5. Evidence statements
  • 5.6. Evidence to recommendations
  • 5.7. Recommendations and research recommendations
• 6. Medicines-related communication systems when patients move from one care setting to another
  • 6.1. Introduction
  • 6.2. Review question
  • 6.3. Evidence review
  • 6.4. Health economic evidence
  • 6.5. Evidence statements
  • 6.6. Evidence to recommendations
  • 6.7. Recommendations and research recommendations
• 7. Medicines reconciliation
  • 7.1. Introduction
  • 7.2. Review question
  • 7.3. Evidence review
  • 7.4. Health economic evidence
  • 7.5. Evidence statements
  • 7.6. Evidence to recommendations
  • 7.7. Recommendations and research recommendations
• 8. Medication review
  • 8.1. Introduction
  • 8.2. Review question
  • 8.3. Evidence review
  • 8.4. Health economic evidence
  • 8.5. Evidence statements
  • 8.6. Evidence to recommendations
  • 8.7. Recommendations and research recommendations
• 9. Self-management plans
  • 9.1. Introduction
  • 9.2. Review question
  • 9.3. Evidence review
  • 9.4. Health economic evidence
  • 9.5. Evidence statements
  • 9.6. Evidence to recommendations
  • 9.7. Recommendations and research recommendations
• 10. Patient decision aids used in consultations involving medicines
  • 10.1. Introduction
  • 10.2. Review question
  • 10.3. Evidence review
  • 10.4. Health economic evidence
  • 10.5. Evidence statements
  • 10.6. Evidence to recommendations
  • 10.7. Recommendations and research recommendations
• 11. Clinical decision support
  • 11.1. Introduction
  • 11.2. Review question
  • 11.3. Evidence review
  • 11.4. Health economic evidence
  • 11.5. Evidence statements
  • 11.6. Evidence to recommendations
  • 11.7. Recommendations and research recommendations
• Medicines-related models of organisational and cross-sector working
  • 12.1. Introduction
  • 12.2. Review question
  • 12.3. Evidence review
  • 12.4. Health economic evidence
  • 12.5. Evidence statements
  • 12.6. Evidence to recommendations
  • 12.7. Recommendations and research recommendations
• 13. Reference list
• 14. Glossary
• Appendices
  • Appendix A. Guideline Development Group Declarations of Interest
  • Appendix B. Scope
  • Appendix C. How this guideline was developed
  • Appendix D. Clinical Evidence Tables and GRADE profiles
  • Appendix E. Economic Evidence Tables
  • Appendix F. Cost Analysis and Full Health Economics Report

NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales.

This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, and informed by the summary of product characteristics of any drugs.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.